One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

21 March 2017, 09:58

Is Dolutegravir Monotherapy Effective in Treating HIV?

Is Dolutegravir Monotherapy Effective in Treating HIV? - picture 1

The authors of the multicenter study performed in the Netherlands hypothesised that Dolutegravir (DTG) monotherapy (DTG 50 mg by mouth daily) was non-inferior to ART in sustaining virologic suppression. The results of this study was reported at CROI 2017.

Although dolutegravir (#DTG) is known for its high genetic barrier to resistance, its durability to sustain virologic suppression had not previously been evaluated. Typically, effective ART consists of 3 antiretrovirals from at least two drug classes. Simplification of ART comes with the advantages of reduced costs, toxicity, pill burden, and a potential for drug-drug interactions.

A total of 96 patients received DTG-monotherapy, where 94 reached 24 weeks with viral load less than 200 copies/mL. 77 out of 96 participants made it to weeks with viral load less than 200 copies/mL of DTG-monotherapy. In total, 8 participants developed virological failure, and 3 participants were found to have developed integrase resistance.

The results of this study demonstrate that although DTG-monotherapy was non-inferior to ART at 24 weeks with viral load less than 200 copies/mL, virological failure continued to develop after 24 weeks leading to the development of integrase resistance in 3 patients. Therefore, the genetic barrier to resistance against DTG was inferior and should not be used as monotherapy for HIV maintenance therapy.

Author: Lilia Ten

Share on social media